News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cardio3 BioSciences To Enroll The 120th Patient For Its CHART-1 Study



7/7/2014 10:24:55 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Mont-Saint-Guibert, Belgium, - Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of advanced regenerative therapies for heart disease, announces today that it has enrolled the 120th patient in its phase III clinical study CHART-1, aimed at evaluating the potential of its product candidate C-Cure® for the treatment of heart failure. This represents the half of patients to be recruited into CHART-1.

With over 25 active centers in 10 countries, the Company is in line with its goal of completing the recruitment of all patients by the end of 2014.

CHART-1 is a prospective, multi-centre, randomized, sham-controlled, patient-and evaluator-blinded study comparing treatment with C-Cure® to a sham treatment. The trial will recruit a minimum of 240 patients with chronic advanced symptomatic heart failure. The primary endpoint of the trial is a composite endpoint including mortality, morbidity, quality of life, Six Minute Walk Test and left ventricular structure and function at 9 months post-procedure. This study represents the world’s first Phase III trial for a pre-programmed cellular therapy targeting heart failure.

To date, no incidents reported in the study call into question the continuation thereof. The safety analysis during the third quarter and futility analysis around the end of this year are the next steps in the study.

Dr Christian Homsy, CEO of Cardio3 BioSciences, comments: “We are very pleased to announce the recruitment of the 120th patient that keeps us on target with our goal of enrolment. This is an important milestone that demonstrates the momentum seen into the start of 2014. Everyday, thanks to the commitment of our teams and clinical centers that combine enthusiasm and competence, we are coming closer to our goal which is to bring a totally new and different treatment to thousands of patients suffering from heart failure."

For more information contact:
Cardio3 BioSciences
Dr Christian Homsy, CEO
Anne Portzenheim, Communication Manager
www.c3bs.com
Tel : +32 10 39 41 00
aportzenheim@c3bs.com

Citigate Dewe Rogerson
Chris Gardner
Tel : +44 (0) 207 638 9571

About Cardio3 BioSciences
Cardio3 BioSciences is a Belgian leading biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases. The company was founded in 2007 and is based in the Walloon region of Belgium. Cardio3 BioSciences leverages research collaborations in the US and in Europe with Mayo Clinic and the Cardiovascular Centre Aalst, Belgium.

The Company’s lead product candidate C-Cure® is an innovative pharmaceutical product that is being developed for heart failure indication. C-Cure® consists of a patient’s own cells that are harvested from the patient’s bone marrow and engineered to become new heart muscle. This process is known as Cardiopoiesis.

Cardio3 BioSciences has also developed C-Cath®ez, the most technologically advanced injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium.

Cardio3 BioSciences’ shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES